Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
2.150
-0.080 (-3.59%)
At close: Oct 27, 2025, 4:00 PM EDT
2.190
+0.040 (1.86%)
Pre-market: Oct 28, 2025, 8:42 AM EDT
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$462,100
Profits / Employee
-$1,101,310
Market Cap
460.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% |
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IVVD News
- 22 days ago - Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 4 weeks ago - Invivyd Appoints Paul B. Bolno, M.D. - GlobeNewsWire
- 5 weeks ago - Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer - GlobeNewsWire
- 7 weeks ago - SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 - GlobeNewsWire
- 2 months ago - Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions - Seeking Alpha
- 2 months ago - Invivyd to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire